Deutsche Bank AG Buys 63,512 Shares of Prothena Co. plc (NASDAQ:PRTA)

Deutsche Bank AG increased its position in shares of Prothena Co. plc (NASDAQ:PRTA - Free Report) by 195.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 95,970 shares of the biotechnology company's stock after acquiring an additional 63,512 shares during the quarter. Deutsche Bank AG owned about 0.18% of Prothena worth $1,329,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in the company. Wellington Management Group LLP raised its holdings in Prothena by 22.8% during the 4th quarter. Wellington Management Group LLP now owns 5,130,876 shares of the biotechnology company's stock worth $71,063,000 after purchasing an additional 952,088 shares during the last quarter. Vanguard Group Inc. grew its position in shares of Prothena by 11.5% during the 4th quarter. Vanguard Group Inc. now owns 1,403,838 shares of the biotechnology company's stock worth $19,443,000 after buying an additional 144,737 shares during the period. Dimensional Fund Advisors LP raised its stake in shares of Prothena by 1.3% during the fourth quarter. Dimensional Fund Advisors LP now owns 864,833 shares of the biotechnology company's stock worth $11,980,000 after buying an additional 10,783 shares during the last quarter. Federated Hermes Inc. lifted its holdings in Prothena by 84.3% in the fourth quarter. Federated Hermes Inc. now owns 746,177 shares of the biotechnology company's stock valued at $10,335,000 after buying an additional 341,274 shares during the period. Finally, Boxer Capital Management LLC bought a new position in Prothena in the fourth quarter valued at approximately $9,556,000. Institutional investors own 97.08% of the company's stock.

Analyst Upgrades and Downgrades

PRTA has been the subject of several recent research reports. Cantor Fitzgerald cut shares of Prothena from an "overweight" rating to a "neutral" rating in a research report on Tuesday. Jefferies Financial Group downgraded Prothena from a "buy" rating to a "hold" rating and set a $6.00 price objective for the company. in a report on Tuesday. Piper Sandler cut their target price on Prothena from $110.00 to $81.00 and set an "overweight" rating on the stock in a research note on Tuesday. HC Wainwright decreased their target price on Prothena from $30.00 to $14.00 and set a "buy" rating for the company in a research report on Tuesday. Finally, Royal Bank of Canada cut their price target on shares of Prothena from $24.00 to $20.00 and set a "sector perform" rating on the stock in a research report on Friday, February 21st. One investment analyst has rated the stock with a sell rating, five have given a hold rating and four have assigned a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Hold" and an average price target of $31.50.

Prothena Stock Performance

PRTA stock traded up $0.10 during mid-day trading on Thursday, hitting $4.70. 5,378,265 shares of the company were exchanged, compared to its average volume of 681,430. Prothena Co. plc has a 1-year low of $4.32 and a 1-year high of $25.42. The firm's 50 day simple moving average is $9.04 and its 200 day simple moving average is $12.57. The firm has a market cap of $252.99 million, a P/E ratio of -2.04 and a beta of 0.11.

Prothena (NASDAQ:PRTA - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The biotechnology company reported ($1.12) EPS for the quarter, missing analysts' consensus estimates of ($0.92) by ($0.20). The company had revenue of $2.83 million for the quarter, compared to analyst estimates of $8.18 million. Prothena had a negative return on equity of 22.67% and a negative net margin of 90.50%. The company's revenue was up 5500.0% on a year-over-year basis. During the same quarter in the previous year, the business earned ($1.34) earnings per share. On average, equities research analysts predict that Prothena Co. plc will post -4.04 EPS for the current fiscal year.

Prothena Profile

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease.